Amantadine
| Evidence Level: L5 | Predicted Indications: 4 |
Table of Contents
- Amantadine
- Pharmacist Assessment Report
- Amantadine: NMDA receptor antagonist and dopaminergic agent → Rasmussen subacute encephalitis
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Canada Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Amantadine: NMDA receptor antagonist and dopaminergic agent → Rasmussen subacute encephalitis
One-Sentence Summary
Amantadine is a drug marketed in Canada as single-ingredient syrup and capsule products. The TxGNN model predicts it may be effective for Rasmussen subacute encephalitis, with a score of 0.9948. There are currently no clinical trials and no publications supporting this specific prediction, so it rests on model output alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Rasmussen subacute encephalitis |
| TxGNN Prediction Score | 0.9948 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 3 of 3) |
| Number of DINs | 3 (marketed: 3) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data are not available in the data compiled for this report. Amantadine is generally known to act as an NMDA receptor antagonist with dopaminergic effects, but this was not confirmed in the data provided here.
One possible link is that blocking NMDA receptors could counter glutamate-mediated excitotoxicity, which is thought to contribute to seizures and neuronal injury in Rasmussen encephalitis, an immune-mediated epilepsy. This is a hypothesis only. No trials or publications in the data compiled for this report study amantadine in this disease, so the prediction cannot be verified from the available evidence.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02538601 | ODAN-AMANTADINE SYRUP | Syrup | Not recorded |
| 02022826 | PDP-AMANTADINE HYDROCHLORIDE SYRUP | Syrup | Not recorded |
| 01990403 | PDP-AMANTADINE HYDROCHLORIDE CAPSULES | Capsule | Not recorded |
Safety Considerations
- Drug Interactions: 93 interactions were recorded. The main ones listed include:
- Major: Bupropion
- Moderate: anticholinergic agents (atropine, clidinium, dicyclomine, glycopyrronium, hyoscyamine, mepenzolate, methscopolamine, propantheline, scopolamine, trospium), metoclopramide, polyethylene glycol (3350 with electrolytes), picosulfuric acid, and sodium sulfate
- Conditions flagged as contraindication-related in the compiled data (not taken from label text): multiple system atrophy, postural orthostatic tachycardia syndrome, orthostatic hypotension, epilepsy, kidney disease, congestive heart failure, psychotic and other mental disorders, angle-closure glaucoma, substance-related disorders, melanoma, and atopic eczema/dermatitis.
Please refer to the package insert for full warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction score is very high (0.9948), but no clinical trials or publications study amantadine in Rasmussen encephalitis, so the evidence level is L5 (model prediction only).
To proceed, the following is needed:
- Mechanism of action data to support a link to Rasmussen encephalitis
- Preclinical or clinical studies of amantadine in this disease
- Package insert warnings and contraindications from Health Canada
- Safety assessment for patients with epilepsy, given the flagged epilepsy-related contraindication relation
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.